KALA BIO (27F0) Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
27F0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
KALA BIO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$16.99 |
| 52 Week Low | US$0.44 |
| Beta | -2.51 |
| 1 Month Change | -41.57% |
| 3 Month Change | -62.71% |
| 1 Year Change | -93.67% |
| 3 Year Change | -98.06% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 27F0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.5% | 3.5% | 0.8% |
| 1Y | -93.7% | -30.8% | 13.6% |
Return vs Industry: 27F0 underperformed the German Biotechs industry which returned -30.8% over the past year.
Return vs Market: 27F0 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| 27F0 volatility | |
|---|---|
| 27F0 Average Weekly Movement | 36.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 27F0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 27F0's weekly volatility has increased from 26% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 38 | David Lazar | www.kalarx.com |
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases.
KALA BIO, Inc. Fundamentals Summary
| 27F0 fundamental statistics | |
|---|---|
| Market cap | €12.32m |
| Earnings (TTM) | -€30.59m |
| Revenue (TTM) | n/a |
Is 27F0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 27F0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.84m |
| Earnings | -US$35.84m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -327.9% |
How did 27F0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 20:25 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KALA BIO, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Biren Amin | Jefferies LLC |
| Christopher Neyor | J.P. Morgan |